Cherry Creek Investment Advisors Inc. bought a new position in Stereotaxis, Inc. (NYSEAMERICAN:STXS) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 25,578 shares of the company’s stock, valued at approximately $247,000.
A number of other large investors have also modified their holdings of the business. BlackRock Inc. raised its position in Stereotaxis by 16.7% in the 2nd quarter. BlackRock Inc. now owns 3,310,686 shares of the company’s stock worth $31,915,000 after buying an additional 473,137 shares during the last quarter. Redmile Group LLC raised its position in Stereotaxis by 4.5% in the 1st quarter. Redmile Group LLC now owns 3,241,603 shares of the company’s stock worth $21,784,000 after buying an additional 138,276 shares during the last quarter. Geode Capital Management LLC raised its position in Stereotaxis by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 883,997 shares of the company’s stock worth $8,521,000 after buying an additional 52,531 shares during the last quarter. Parkman Healthcare Partners LLC grew its stake in shares of Stereotaxis by 4.4% during the 1st quarter. Parkman Healthcare Partners LLC now owns 675,922 shares of the company’s stock valued at $4,542,000 after purchasing an additional 28,379 shares during the period. Finally, Calamos Advisors LLC bought a new stake in shares of Stereotaxis during the 2nd quarter valued at about $6,370,000. 58.38% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have issued reports on STXS shares. Piper Sandler restated an “overweight” rating and set a $11.00 price target (up from $9.00) on shares of Stereotaxis in a research note on Thursday, July 1st. Zacks Investment Research upgraded Stereotaxis from a “sell” rating to a “hold” rating in a research note on Wednesday, September 1st. Finally, Lake Street Capital boosted their price target on Stereotaxis from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, June 25th.
Stereotaxis (NYSEAMERICAN:STXS) last announced its quarterly earnings data on Tuesday, August 10th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.01. The company had revenue of $9.05 million during the quarter, compared to the consensus estimate of $8.20 million. Stereotaxis had a negative return on equity of 15.61% and a negative net margin of 16.55%. On average, research analysts predict that Stereotaxis, Inc. will post -0.12 EPS for the current year.
Stereotaxis Company Profile
Stereotaxis, Inc designs, manufactures and markets robotic magnetic navigation systems for use in a hospital’s interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System.
Further Reading: What is the price-sales ratio?
Want to see what other hedge funds are holding STXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stereotaxis, Inc. (NYSEAMERICAN:STXS).
Receive News & Ratings for Stereotaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stereotaxis and related companies with MarketBeat.com's FREE daily email newsletter.